Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III idebenone versus placebo in Duchenne muscular dystrophy
NL-OMON32760Phase 3Active, not recruiting
- Sponsor
- Santhera Pharmaceuticals
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing Idebenone with Placebo (2 arms). Primary endpoint: Change from baseline to Week 52 in percent predicted peak expiratory flow. Started Jul 2010; status: active, not recruiting.
02
Drugs
idebenone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON32760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32760.